Anti-endotoxin monoclonal antibodies

New England Journal of Medicine

Volumn 326, Issue 17, 1992, Pages 1153-1157

  Warren, H Shaw ^a   Danner, Robert L ^b   Munford, Robert S ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTOXIN; ENDOTOXIN; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E5; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; DRUG EFFICACY; GRAM NEGATIVE SEPSIS; HUMAN; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL;

EID: 0026552353     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199204233261711     Document Type: Editorial

References (36)

1. Greenman R.L., Schein R.M.H., Martin M.A., et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266:1097-1102
2. Ziegler E.J., Fisher C.J. Jr., Sprung C.L., et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin — a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324:429-436
3. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991. (Obtained through the Freedom of Information Act.)
4. Gazzano-Santoro H., Parent J.B., Wood D.M., et al. Reactivity of E5 monoclonal antibody to smooth lipopolysaccharides. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 29—October 2, 1991. Washington, D.C.: American Society for Microbiology, 1991: 230. abstract.
5. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991: 179-85. (Obtained through the Freedom of Information Act.)
6. Wheeler A.P., Hardie W.D., Bernard G. Studies of an antiendotoxin antibody in preventing the physiologic changes of endotoxemia in awake sheep. Am Rev Respir Dis 1990; 142:775-781
7. Young L.S., Gascon R., Alam S., Bermudez L.E.M. Monoclonal antibodies for treatment of gram-negative infections. Rev Infect Dis 1989; 11:Suppl 7:S1564-S1571.
8. Bogard W.C. Jr., Siegel S.A. The human monoclonal antibody HA-1A: studies on the epitope location within the endotoxin molecule and epitopic exposure on the surface of viable gram-negative bacteria. Circ Shock 1991; 34:119. abstract.
9. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991: 41-43. (Obtained through the Freedom of Information Act.)
10. Teng N.N.H., Kaplan H.S., Hebert J.M., et al. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci U S A 1985; 82:1790-1794
11. Baumgartner J.-D., Heumann D., GlauserM- P. The HA-1A monoclonal antibody for gram-negative sepsis. N Engl J Med 1991; 325:281-282
12. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991: 82-84. (Obtained through the Freedom of Information Act.)
13. Ziegler E.J., Teng N.N.H., Douglas H., Wunderlich A., Berger H.J., Bolmer S.D. Treatment of Pseudomonas bacteremia in neutropenic rabbits with human monoclonal IgM antibody against E. coli lipid A. Clin Res 1987; 35:619A. abstract.
14. Feeley T.W., Minty B.D., Scudder C.M., Jones J.G., Royston D., Teng N.N.H. The effect of human antiendotoxin monoclonal antibodies on endotoxininduced lung injury in the rat. Am Rev Respir Dis 1987; 135:665-670
15. Tune B.M., Hsu C.Y., Bieber M.M., Teng N.N.H. Effects of anti-lipid A human monoclonal antibody on lipopolysaccharide-induced toxicity to the kidney. J Urol 1989; 141:1463-1466
16. Baumgartner J.D., Heumann D., Gerain J., Weinbreck P., Grau G.E., Glauser M.P. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6: comparison of O side chain-specific antibodies with core LPS antibodies. J Exp Med 1990; 171:889-896
17. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991:50. (Obtained through the Freedom of Information Act.)
18. Zanetti G., Glauser M.P., Baumgartner J.D. Use of immunoglobulins in prevention and treatment of infection in critically ill patients: review and critique. Rev Infect Dis 1991; 13:985-992
19. Wenzel R., Bone R., Fein A., et al. Results of a second double-blind, randomized, controlled trial of antiendotoxin antibody E5 in gram-negative sepsis. In: Program and abstracts of the 31 st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 29—October 2, 1991. Washington, D.C.: American Society for Microbiology, 1991: 294. (and extended abstract.)
20. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991: 99-124. (Obtained through the Freedom of Information Act.)
21. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991: 104-7. (Obtained through the Freedom of Information Act.)
22. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991:118. (Obtained through the Freedom of Information Act.)
23. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991:109. (Obtained through the Freedom of Information Act.)
24. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991: 111-2. (Obtained through the Freedom of Information Act.)
25. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991: 116-7. (Obtained through the Freedom of Information Act.)
26. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991:148. (Obtained through the Freedom of Information Act.)
27. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification. Crit Care Med 1985; 13:818-829
28. Knaus W.A., Wagner D.P., Lynn J. Short-term mortality predictions for critically ill hospitalized adults: science and ethics. Science 1991; 254:389-394
29. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991:144. (Obtained through the Freedom of Information Act.)
30. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991: 114-5. (Obtained through the Freedom of Information Act.)
31. Open Meeting of the Vaccines and Related Biological Products Advisory Committee, September 4, 1991. Vol. 1. Bethesda, Md.: Food and Drug Administration, 1991:154. (Obtained through the Freedom of Information Act.)
32. Schumr W. Steroids in the treatment of clinical septic shock. Ann Surg 1976; 184:333-341
33. Sprung C.L., Caralis P.V., Marcial E.H., et al. The effects of high-dose corticosteroids in patients with septic shock — a prospective, controlled study. N Engl J Med 1984; 311:1137-1143
34. Bone R.C., Fisher C.J. Jr., Clemmer T.P., et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-658
35. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317:659-665
36. Ziegler E.J., McCutchan J.A., Fierer J., et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307:1225-1230